Pharmacokinetics and biliary excretion of mitoxantrone in rats

Journal of Pharmaceutical Sciences

Volumn 99, Issue 5, 2010, Pages 2502-2510

  Yang, Xinning ^a   Morris, Marilyn E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Active transport; Biliary clearance; Biliary excretion; Breast cancer resistance protein; Mitoxantrone; P glycoprotein; Pharmacokinetics; QSAR; QSPKR; Rat

Indexed keywords

AMETANTRONE; AMETANTRONE DIACETATE; ELACRIDAR; GLYCOPROTEIN P; MITOXANTRONE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILE DUCT; BILIARY EXCRETION; BLOOD SAMPLING; BOLUS INJECTION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT;

EID: 77951265203     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22011     Document Type: Article

References (35)

1. Batra VK, Morrison JA, Woodward DL, Siverd NS, Yacobi A. 1986. Pharmacokinetics of mitoxantrone in man and laboratory animals. Drug Metab Rev 17:311-329.
2. Chau M, Christensen JL, Ajami AM, Capizzi RL. 2008. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. Leuk Res 32:465-473.
3. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
4. Minderman H, O'Loughlin KL, Pendyala L, Baer MR. 2004. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10:1826-1834.
5. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE. 1999. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. Cancer Res 59:8-13.
6. Ando T, Kusuhara H, Merino G, Alvarez AI, Schinkel AH, Sugiyama Y. 2007. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos 35:1873-1879.
7. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. 2005. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800-807.
8. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. 2000. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
9. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. 2005. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 67:1758-1764.
10. Angelin B, Arvidsson A, Dahlqvist R, Hedman A, Schenck-Gustafsson K. 1987. Quinidine reduces biliary clearance of digoxin in man. Eur J Clin Invest 17:262-265.
11. Kageyama M, Fukushima K, Togawa T, Fujimoto K, Taki M, Nishimura A, Ito Y, Sugioka N, Shibata N, Takada K. 2006. Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers. Biol Pharm Bull 29:779-784.
12. Lam JL, Okochi H, Huang Y, Benet LZ. 2006. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: Characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos 34:1336-1344.
13. Krishna R, McIntosh N, Riggs KW, Mayer LD. 1999. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. Clin Cancer Res 5:2939-2947.
14. Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL. 1985. Disposition of mitoxantrone in cancer patients. Cancer Res 45:1879-1884.
15. Savaraj N, Lu K, Manuel V, Loo TL. 1982. Pharmacology of mitoxantrone in cancer patients. Cancer Chemother Pharmacol 8:113-117.
16. Avramis V. 1982. Pharmacokinetics of dihydroxyanthracenedione (DHAD) and ils melaboliles in rats. Pharmacologist 24:241.
17. 14C-mitoxantrone in the rat following different intravenous doses and characleristics of drug related material in the bile. Fed Proc 43:345.
18. Ehninger G, Proksch B, Hartmann F, Gartner HV, Wilms K. 1984. Mitoxantrone metabolism in the isolated perfused rat liver. Cancer Chemother Pharmacol 12:50-52.
19. Yang X, Gandhi Y, Duignan DB, Morris ME. 2009. Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships. AAPS J 11:511-525.
20. Lacayo NJ, Lum BL, Becton DL, Weinstein H, Ravindranath Y, Chang MN, Bomgaars L, Lauer SJ, Sikic BI, Dahl GV. 2002. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 16:920-927.
21. An G, Morris ME. HPLC Analysis of Mitoxantrone in Mouse Plasma and Tissues: Application in a Pharmacokinetic Study. J Pharm Biomed Anal. Sep 27. [Epub ahead of print].
22. Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL. 1983. Disposition of mitoxantrone in patients. Cancer Treat Rev 10(suppl B):23-27.
23. Richard B, Fabre G, Fabre I, Cano JP. 1989. Excretion and metabolism of mitoxantrone in rabbits. Cancer Res 49:833-837.
24. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. 2004. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64:3296-3301.
25. Wolf CR, Macpherson JS, Smyth JF. 1986. Evidence for the metabolism of mitozantrone by microsomal glutathione transferases and 3-methylcholanthrene- inducible glucuronosyl transferases. Biochem Pharmacol 35:1577-1581.
26. Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, Sugiyama Y. 2004. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol Pharmacol 66:450-459.
27. Nicolau G, Szucs-Myers V, McWilliams W, Morrison J, Lanzilotti A. 1985. Radioimmunoassay for mitoxantrone, a new antitumor agent. Invest New Drugs 3:51-56.
28. Lu K, Savaraj N, Loo TL. 1984. Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10- anthracenedione dihydrochloride in the dog. Cancer Chemother Pharmacol 13:63-66.
29. Ramirez LH, Zhao Z, Rougier P, Bognel C, Dzodic R, Vassal G, Ardouin P, Gouyette A, Munck JN. 1996. Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbits. Cancer Chemother Pharmacol 37:371-376.
30. Ehninger G, Proksch B, Heinzel G, Schiller E, Weible KH, Woodward DL. 1985. The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs 3:109-116.
31. Schleyer E, Kamischke A, Kaufmann CC, Unterhalt M, Hiddemann W. 1994. New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. Leukemia 8:435-440.
32. Zhang S, Yang X, Coburn RA, Morris ME. 2005. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 70:627-639.
33. Ng C, Xiao Y, Putnam W, Lum B, Tropsha A. 2004. Quantitative structure-pharmacokinetic parameters relationships (QSPKR) analysis of antimicrobial agents in humans using simulated annealing k-nearest-neighbor and partial least-square analysis methods. J Pharm Sci 93:2535-2544.
34. Ahmad A, Wang YF, Ahmad I. 2005. Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: Pharmacokinetics in mice. Methods Enzymol 391:176-185.
35. Mager DE, Jusko WJ. 2002. Quantitative structure-pharmacokinetic/ pharmacodynamic relationships of corticosteroids in man. J Pharm Sci 91:2441-2451.